126 related articles for article (PubMed ID: 18817993)
1. Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound.
Nakayama T; Komiyama N; Yokoyama M; Namikawa S; Kuroda N; Kobayashi Y; Komuro I
Int J Cardiol; 2010 Jan; 138(2):157-65. PubMed ID: 18817993
[TBL] [Abstract][Full Text] [Related]
2. Plasma low-density lipoprotein reduction and structural effects on coronary atherosclerotic plaques by atorvastatin as clinically assessed with intravascular ultrasound radio-frequency signal analysis: a randomized prospective study.
Yokoyama M; Komiyama N; Courtney BK; Nakayama T; Namikawa S; Kuriyama N; Koizumi T; Nameki M; Fitzgerald PJ; Komuro I
Am Heart J; 2005 Aug; 150(2):287. PubMed ID: 16086932
[TBL] [Abstract][Full Text] [Related]
3. Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study.
Nicholls SJ; Tuzcu EM; Wolski K; Bayturan O; Lavoie A; Uno K; Kupfer S; Perez A; Nesto R; Nissen SE
J Am Coll Cardiol; 2011 Jan; 57(2):153-9. PubMed ID: 21211686
[TBL] [Abstract][Full Text] [Related]
4. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta.
Mizoguchi M; Tahara N; Tahara A; Nitta Y; Kodama N; Oba T; Mawatari K; Yasukawa H; Kaida H; Ishibashi M; Hayabuchi N; Harada H; Ikeda H; Yamagishi S; Imaizumi T
JACC Cardiovasc Imaging; 2011 Oct; 4(10):1110-8. PubMed ID: 21999871
[TBL] [Abstract][Full Text] [Related]
5. Effect of pioglitazone on cardiometabolic profiles and safety in patients with type 2 diabetes undergoing percutaneous coronary artery intervention: a prospective, multicenter, randomized trial.
Tanaka A; Komukai S; Shibata Y; Yokoi H; Iwasaki Y; Kawasaki T; Horiuchi K; Nakao K; Ueno T; Nakashima H; Tamashiro M; Hikichi Y; Shimomura M; Tago M; Toyoda S; Inoue T; Kawaguchi A; Node K;
Heart Vessels; 2018 Sep; 33(9):965-977. PubMed ID: 29487991
[TBL] [Abstract][Full Text] [Related]
6. Regression and shift in composition of coronary atherosclerotic plaques by pioglitazone: insight from an intravascular ultrasound analysis.
Clementi F; Di Luozzo M; Mango R; Luciani G; Trivisonno A; Pizzuto F; Martuscelli E; Mehta JL; Romeo F
J Cardiovasc Med (Hagerstown); 2009 Mar; 10(3):231-7. PubMed ID: 19262209
[TBL] [Abstract][Full Text] [Related]
7. Pioglitazone induces regression and stabilization of coronary atherosclerotic plaques in patients with impaired glucose tolerance.
Yang HB; Zhao XY; Zhang JY; Du YY; Wang XF
Diabet Med; 2012 Mar; 29(3):359-65. PubMed ID: 21950726
[TBL] [Abstract][Full Text] [Related]
8. Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
Nitta Y; Tahara N; Tahara A; Honda A; Kodama N; Mizoguchi M; Kaida H; Ishibashi M; Hayabuchi N; Ikeda H; Yamagishi S; Imaizumi T
JACC Cardiovasc Imaging; 2013 Nov; 6(11):1172-82. PubMed ID: 24229770
[TBL] [Abstract][Full Text] [Related]
9. Pioglitazone reduces the necrotic-core component in coronary plaque in association with enhanced plasma adiponectin in patients with type 2 diabetes mellitus.
Ogasawara D; Shite J; Shinke T; Watanabe S; Otake H; Tanino Y; Sawada T; Kawamori H; Kato H; Miyoshi N; Hirata K
Circ J; 2009 Feb; 73(2):343-51. PubMed ID: 19096190
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of low-dose pioglitazone after primary coronary angioplasty with the use of bare metal stent in patients with acute myocardial infarction and with type 2 diabetes mellitus or impaired glucose tolerance.
Yokoyama J; Sutoh N; Higuma T; Horiuchi D; Katoh C; Yokota T; Echizen T; Sasaki S; Hanada H; Osanai T; Okumura K
Heart Vessels; 2007 May; 22(3):146-51. PubMed ID: 17533517
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study.
Takagi T; Yamamuro A; Tamita K; Yamabe K; Katayama M; Mizoguchi S; Ibuki M; Tani T; Tanabe K; Nagai K; Shiratori K; Morioka S; Yoshikawa J
Am Heart J; 2003 Aug; 146(2):E5. PubMed ID: 12891212
[TBL] [Abstract][Full Text] [Related]
12. Effects of low-dose pioglitazone on glucose control, lipid profiles, renin-angiotensin-aldosterone system and natriuretic peptides in diabetic patients with coronary artery disease.
Kurisu S; Iwasaki T; Ishibashi K; Mitsuba N; Dohi Y; Nishioka K; Kihara Y
J Renin Angiotensin Aldosterone Syst; 2013 Mar; 14(1):51-5. PubMed ID: 22802358
[TBL] [Abstract][Full Text] [Related]
13. Abnormal glucose regulation is associated with lipid-rich coronary plaque: relationship to insulin resistance.
Amano T; Matsubara T; Uetani T; Nanki M; Marui N; Kato M; Yoshida T; Arai K; Yokoi K; Ando H; Kumagai S; Ishii H; Izawa H; Hotta N; Murohara T
JACC Cardiovasc Imaging; 2008 Jan; 1(1):39-45. PubMed ID: 19356403
[TBL] [Abstract][Full Text] [Related]
14. Effects of the PPARγ agonist pioglitazone on coronary atherosclerotic plaque composition and plaque progression in non-diabetic patients: a double-center, randomized controlled VH-IVUS pilot-trial.
Christoph M; Herold J; Berg-Holldack A; Rauwolf T; Ziemssen T; Schmeisser A; Weinert S; Ebner B; Said S; Strasser RH; Braun-Dullaeus RC
Heart Vessels; 2015 May; 30(3):286-95. PubMed ID: 24519403
[TBL] [Abstract][Full Text] [Related]
15. Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus.
Kodama N; Tahara N; Tahara A; Honda A; Nitta Y; Mizoguchi M; Kaida H; Ishibashi M; Abe T; Ikeda H; Narula J; Fukumoto Y; Yamagishi S; Imaizumi T
J Clin Endocrinol Metab; 2013 Nov; 98(11):4438-45. PubMed ID: 24030946
[TBL] [Abstract][Full Text] [Related]
16. Effect of fluvastatin on progression of coronary atherosclerotic plaque evaluated by virtual histology intravascular ultrasound.
Nasu K; Tsuchikane E; Katoh O; Tanaka N; Kimura M; Ehara M; Kinoshita Y; Matsubara T; Matsuo H; Asakura K; Asakura Y; Terashima M; Takayama T; Honye J; Hirayama A; Saito S; Suzuki T
JACC Cardiovasc Interv; 2009 Jul; 2(7):689-96. PubMed ID: 19628194
[TBL] [Abstract][Full Text] [Related]
17. Impact of acarbose on carotid intima-media thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: A one-year, prospective, randomized, open-label, parallel-group study in Japanese adults with established coronary artery disease.
Koyasu M; Ishii H; Watarai M; Takemoto K; Inden Y; Takeshita K; Amano T; Yoshikawa D; Matsubara T; Murohara T
Clin Ther; 2010 Aug; 32(9):1610-7. PubMed ID: 20974318
[TBL] [Abstract][Full Text] [Related]
18. A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study).
Takagi T; Okura H; Kobayashi Y; Kataoka T; Taguchi H; Toda I; Tamita K; Yamamuro A; Sakanoue Y; Ito A; Yanagi S; Shimeno K; Waseda K; Yamasaki M; Fitzgerald PJ; Ikeno F; Honda Y; Yoshiyama M; Yoshikawa J;
JACC Cardiovasc Interv; 2009 Jun; 2(6):524-31. PubMed ID: 19539256
[TBL] [Abstract][Full Text] [Related]
19. Comparison of bare metal stent with pioglitazone versus sirolimus-eluting stent for percutaneous coronary intervention in patients with Type 2 diabetes mellitus.
Nishio K; Shigemitsu M; Kodama Y; Konno N; Katagiri T; Kobayashi Y
Cardiovasc Revasc Med; 2009; 10(1):5-11. PubMed ID: 19159848
[TBL] [Abstract][Full Text] [Related]
20. Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease.
Forst T; Karagiannis E; Lübben G; Hohberg C; Schöndorf T; Dikta G; Drexler M; Morcos M; Dänschel W; Borchert M; Pfützner A
Atherosclerosis; 2008 Mar; 197(1):311-7. PubMed ID: 17588584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
